TARA
Protara Therapeutics, Inc.
Biotechnology · Healthcare · United States
2.48
close · 2026-10-30
value
24
cheaper than peers24
quality
69
stronger fundamentals69
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.91× | 83 |
| cash flow yield, 3 years ago | -18.1% | 45 |
| cash flow yield, 1 year ago | -24.5% | 43 |
| cash flow yield, 2 years ago | -25.7% | 38 |
| cash flow yield, latest year | -38.5% | 30 |
| earnings yield, latest year | -54.0% | 29 |
| earnings yield, 2 years ago | -144.0% | 25 |
| earnings yield, 1 year ago | -87.5% | 23 |
| earnings yield, 3 years ago | -236.3% | 17 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -45.8% | 67 |
| debt to equity | 1.7% | 61 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $147M |
| free cash flow | -$40.5M |
| employees | 46 |
| first trade | 2014-10-22 |
| next earnings | 2026-08-11 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.34 | -2.17 | -3.57 | -5.86 |
| free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M |
| net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $49,000 | $36,000 | $12,000 | -$29.5M |